BERLIN (Reuters) - Preliminary data from Pfizer and its German partner Biontech on their experimental COVID-19 vaccine are very encouraging, the head of Germany’s Robert Koch institute for infectious diseases (RKI), Lothar Wieler, said on Thursday.
Reporting by Thomas Seythal and Sabine Siebold
Our Standards: The Thomson Reuters Trust Principles.